Background and Objectives: To investigate the association of the Financial Capacity Instrument-Short Form (FCI-SF) performance and timing total scores with brain β-amyloid and cortical thickness in cognitively unimpaired (CU) (at baseline) older adults. Methods: A total of 309 participants (aged 70 years or older) of the Mayo Clinic Study of Aging underwent 11C-Pittsburgh compound B PET amyloid imaging and MRI, and completed the FCI-SF. Abnormal amyloid PET was defined as standardized uptake value ratio ≥1.48 in an Alzheimer disease (AD)-related region of interest and reduced AD signature cortical thickness as ≤2.68 mm (neurodegeneration). A cohort of 218 (of the 309) participants had follow-up visits (every 15 months) with FCI-SF data for longitudinal analysis (number of visits including baseline, median [range]: 2 [2-4]). In the analysis, we used linear regression and mixed-effects models adjusted for age, sex, education, apolipoprotein E ε4 allele status, global cognitive z score, and previous FCI-SF testing. Results: Participants' mean age (SD) was 80.2 (4.8) years (56.3% male individuals). In cross-sectional analysis, abnormal amyloid PET (vs normal) was associated with a lower FCI-SF total score and slower total composite time. In longitudinal analysis, FCI-SF total score declined faster (difference in annualized rate of change, beta coefficient [β] [95% confidence interval (CI)] = -1.123 [-2.086 to -0.161]) and FCI-SF total composite time increased faster (difference in annualized rate of change, β [95% CI] = 16.274 [5.951 to 26.597]) for participants with neurodegeneration at baseline (vs those without). Participants who exhibited both abnormal amyloid PET and neurodegeneration at baseline had a greater increase in total composite time when compared with the group without abnormal amyloid and without neurodegeneration (difference in annualized rate of change, β [95% CI] = 16.750 [3.193 to 30.307]). Discussion: Performance and processing speed on the FCI-SF were associated with imaging biomarkers of AD pathophysiology in CU (at baseline) older adults. Higher burdens of imaging biomarkers were associated with longitudinal worsening on FCI-SF performance. Additional research is needed to delineate further these associations and their predictive utility at the individual person level.
Background and Objectives: To investigate the association of the Financial Capacity Instrument-Short Form (FCI-SF) performance and timing total scores with brain β-amyloid and cortical thickness in cognitively unimpaired (CU) (at baseline) older adults. Methods: A total of 309 participants (aged 70 years or older) of the Mayo Clinic Study of Aging underwent 11C-Pittsburgh compound B PET amyloid imaging and MRI, and completed the FCI-SF. Abnormal amyloid PET was defined as standardized uptake value ratio ≥1.48 in an Alzheimer disease (AD)-related region of interest and reduced AD signature cortical thickness as ≤2.68 mm (neurodegeneration). A cohort of 218 (of the 309) participants had follow-up visits (every 15 months) with FCI-SF data for longitudinal analysis (number of visits including baseline, median [range]: 2 [2-4]). In the analysis, we used linear regression and mixed-effects models adjusted for age, sex, education, apolipoprotein E ε4 allele status, global cognitive z score, and previous FCI-SF testing. Results: Participants' mean age (SD) was 80.2 (4.8) years (56.3% male individuals). In cross-sectional analysis, abnormal amyloid PET (vs normal) was associated with a lower FCI-SF total score and slower total composite time. In longitudinal analysis, FCI-SF total score declined faster (difference in annualized rate of change, beta coefficient [β] [95% confidence interval (CI)] = -1.123 [-2.086 to -0.161]) and FCI-SF total composite time increased faster (difference in annualized rate of change, β [95% CI] = 16.274 [5.951 to 26.597]) for participants with neurodegeneration at baseline (vs those without). Participants who exhibited both abnormal amyloid PET and neurodegeneration at baseline had a greater increase in total composite time when compared with the group without abnormal amyloid and without neurodegeneration (difference in annualized rate of change, β [95% CI] = 16.750 [3.193 to 30.307]). Discussion: Performance and processing speed on the FCI-SF were associated with imaging biomarkers of AD pathophysiology in CU (at baseline) older adults. Higher burdens of imaging biomarkers were associated with longitudinal worsening on FCI-SF performance. Additional research is needed to delineate further these associations and their predictive utility at the individual person level.
Authors: Matthew L Senjem; Jeffrey L Gunter; Maria M Shiung; Ronald C Petersen; Clifford R Jack Journal: Neuroimage Date: 2005-04-12 Impact factor: 6.556
Authors: K L Triebel; R Martin; H R Griffith; J Marceaux; O C Okonkwo; L Harrell; D Clark; J Brockington; A Bartolucci; Daniel C Marson Journal: Neurology Date: 2009-09-22 Impact factor: 9.910
Authors: Luke E Stoeckel; Christopher C Stewart; H Randall Griffith; Kristen Triebel; Ozioma C Okonkwo; Jan A den Hollander; Roy C Martin; Katherine Belue; Jacquelynn N Copeland; Lindy E Harrell; John C Brockington; David G Clark; Daniel C Marson Journal: Brain Imaging Behav Date: 2013-09 Impact factor: 3.978
Authors: Rosebud O Roberts; Yonas E Geda; David S Knopman; Ruth H Cha; V Shane Pankratz; Bradley F Boeve; Robert J Ivnik; Eric G Tangalos; Ronald C Petersen; Walter A Rocca Journal: Neuroepidemiology Date: 2008-02-07 Impact factor: 3.282
Authors: Leslie M Shaw; Magdalena Korecka; Christopher M Clark; Virginia M-Y Lee; John Q Trojanowski Journal: Nat Rev Drug Discov Date: 2007-03-09 Impact factor: 84.694
Authors: Clifford R Jack; Heather J Wiste; Christopher G Schwarz; Val J Lowe; Matthew L Senjem; Prashanthi Vemuri; Stephen D Weigand; Terry M Therneau; Dave S Knopman; Jeffrey L Gunter; David T Jones; Jonathan Graff-Radford; Kejal Kantarci; Rosebud O Roberts; Michelle M Mielke; Mary M Machulda; Ronald C Petersen Journal: Brain Date: 2018-05-01 Impact factor: 13.501
Authors: Maria Vassilaki; Jeremiah A Aakre; Walter K Kremers; Timothy G Lesnick; Michelle M Mielke; Yonas E Geda; Mary M Machulda; David S Knopman; Lesley Butler; Martin Traber; Prashanthi Vemuri; Val J Lowe; Clifford R Jack; Rosebud O Roberts; Ronald C Petersen Journal: Ann Clin Transl Neurol Date: 2020-04-21 Impact factor: 4.511